Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1
Vladislav I. Deigin · 2013 · EP2046778B1 · patent family 38996830
Published 2013-12-04.
Reported patent results
Reported findings
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Protein-antigen response | A tested cyclic compound reportedly increased antibody titers by 74% | A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result |
| Oral activity comparison | Some cyclic analogues retained oral analgesic activity where comparator peptides did not | Different neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective |
Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Platform context. The family concerns cyclic piperazine-based immunomodulatory compounds related to the chemistry discussed for CP-88 and AWE18.
The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
- Publication
- EP2046778B1 ↗ · 2013-12-04
- Earliest priority / filing
- 2006-08-04 / 2007-08-01
- Original applicant / assignee
- Manus Pharmaceuticals Canada Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 38996830 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Multifunctional bioactive compounds
Inventors: Vladislav I. Deigin.
EP2046778B1 · US8637521B2 · JP5357022B2 · CN101511823B · AU2007280995C1 · BRPI0714616A2 · CA2659875C · EA018548B1 · MX2009001351A · WO2008014613A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
- Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-38996830. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladislav I. Deigin. Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1 EP2046778B1 · patent family 38996830 2013.
Molekul research summary: https://molekul.io/research/patent-ep2046778b1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
CP-88
Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.
AWE18
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.